Factor 8 Ehl denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Extended Half-Life Factor VIII as Not FDA-Approved

A "not FDA-approved" denial for an extended half-life (EHL) Factor VIII product is most often a coding or submission error rather than a substantive coverage dispute. EHL Factor VIII products approved for Hemophilia A carry full FDA Biologics License Application (BLA) approval. This denial typically arises when the NDC or billing code submitted does not match the product's approved indication in the claim system, when a specific EHL product is newer and not yet loaded in Humana's formulary database, or — less commonly — when the submitted indication does not match the label's approved use (for example, using the product off-label for a different bleeding disorder).

## Why This Denial Is Appealable

If the product is FDA-approved for Hemophilia A and the patient has Hemophilia A, the denial basis is factually incorrect and should be overturned on appeal with minimal documentation. Even where off-label use is involved, many states and federal mandates require coverage of off-label use supported by recognized compendia or peer-reviewed literature.

## Federal Appeal Rights

• ERISA §503: Full-and-fair internal review; external review available after exhaustion.
• ACA §2719: Independent external review by an IRO. The request window generally runs approximately four months from the denial — verify the exact date on your denial letter.
• Expedited option: Available if delay would seriously jeopardize health.

## Appeal Process and Timeline

1. Contact Humana's Provider Services line first to verify whether the denial was a billing/coding error — a corrected claim can resolve this without a formal appeal. 2. If a formal appeal is necessary, file within the deadline on the denial letter (often 60–180 days depending on plan type). 3. Include FDA approval documentation and the product's full prescribing label. 4. If the internal appeal is denied, request external IRO review within four months of the final internal denial.

## Documentation to Gather

• FDA BLA approval letter or product labeling: Obtain the full prescribing label from the manufacturer's website or the FDA's Drugs@FDA database — this is the primary document that refutes the denial.
• Correct NDC and HCPCS billing codes: Confirm with the dispensing specialty pharmacy that the codes submitted match the approved product exactly.
• Diagnosis confirmation: Chart documentation of Hemophilia A confirming the on-label indication.
• Prescriber letter: Brief attestation that the product is being used for its FDA-approved indication.

## Criteria-Mapping Structure

This appeal is document-driven rather than criteria-driven. Build a short exhibit package:

| Required Showing | Document | |---|---| | Product has FDA approval | FDA label / BLA reference | | Approved indication matches patient diagnosis | Diagnosis documentation + label indication section | | Correct billing codes used | Corrected claim / pharmacy invoice |

Attach the FDA label as Exhibit A. In most cases, this denial reverses at the first internal level once reviewers see the approval documentation.